Givinostat (HDAC inhibitor)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-03-25 — Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera: First head-to-head clinical trial (trial-late) comparing givinostat directly against hydroxyurea in JAK2V617F-positive high-risk PV; efficacy and safety endpoints under evaluation. (novelty: 4)
Open questions
Related
Contributing findings
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
25-mar-2026
novelty 4
per-area 4
introduces